Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL897853 | 0.86 | CDC25B (0.38) | ALDH1A1MAPTPKMMAPK10NPSR1 | |
| SCHEMBL1899511 | 0.74 | ABCG2 (0.35) | — | |
| SCHEMBL4302368 | 0.73 | ABCG2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL5486774 | 0.73 | ABCG2 (0.31) | — | |
| SCHEMBL31264360 | 0.69 | PTAFR (0.33) | — | |
| SCHEMBL3905504 | 0.69 | MAPT (0.34) | ALDH1A1MAPTPKMMAPK10NPSR1 | |
| Hydrochloric Acid SCHEMBL7482838 | 0.68 | MAPT (0.33) | ALDH1A1MAPTPKMMAPK10NPSR1 | |
| Hydrochloric Acid SCHEMBL7484754 | 0.68 | MAPT (0.33) | ALDH1A1MAPTPKMMAPK10NPSR1 | |
| SCHEMBL8890839 | 0.67 | MAPT (0.35) | ALDH1A1MAPTPKMMAPK10NPSR1 | |
| SCHEMBL4132834 | 0.66 | MAPT (0.37) | ALDH1A1MAPTPKMMAPK10NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-7951743-B2 | Preparation of ultra high molecular weight linear low density polyethylene | EQUISTAR CHEMICALS, LP (US) | 2011-05-31 | — | — | US | disclosed |
| US-7855255-B2 | Preparation of multimodal polyethylene | EQUISTAR CHEMICALS, LP (US) | 2010-12-21 | — | — | US | disclosed |
| US-7829641-B2 | Process for the preparation of multimodal polyethylene resins | EQUISTAR CHEMICALS, LP (US) | 2010-11-09 | — | — | US | disclosed |
| US-7666961-B2 | Olefin polymerization process | EQUISTAR CHEMICALS, LP (US) | 2010-02-23 | — | — | US | disclosed |
| US-20100016526-A1 | Process for the preparation of multimodal polyethylene resins | EQUISTAR CHEMICALS, LP | 2010-01-21 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| EP-1567561-B1 | BIMETALLIC INDENOINDOLYL CATALYSTS | EQUISTAR CHEM LP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090099316-A1 | Preparation of multimodal polyethylene | EQUISTAR CHEMICALS, LP | 2009-04-16 | — | — | US | disclosed |
| WO-2009032050-A1 | OLEFIN POLYMERIZATION PROCESS | EQUISTAR CHEMICALS, LP (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2002081529-A2 | BIMETALLIC CATALYSTS FOR OLEFIN POLYMERIZATION | EQUISTAR CHEMICALS, LP (US) | 2002-10-17 | — | — | WO | disclosed |
| US-6440889-B1 | OLEFIN POLYMERIZATION CATALYSTS; GROUP 4 METAL COMPLEXES WITH SINGLE ANIONIC INDENOINDOLYL LIGAND; REACTING AN INDENOINDOLE WITH TETRAKIS(DIALKYLAMINO) ZIRCONIUM COMPOUND; HALOGENATING; REACTING WITH A CYCLOPENTADIENYL ANION | EQUISTAR CHEMICALS, LP | 2002-08-27 | — | — | US | disclosed |
| US-6414162-B1 | ORGANOMETALLIC COMPLEX WHICH COMPRISES AT LEAST ONE GROUP 3-10 TRANSITION OR LANTHANIDE METAL AND AT LEAST ONE DIANIONIC INDENOINDOLYL LIGAND THAT IS PI- OR SIGMA-BONDED TO METAL | EQUISTAR CHEMICALS, LP | 2002-07-02 | — | — | US | disclosed |
| US-6376629-B2 | ORGANOMETALLIC COMPOUND | EQUISTAR CHEMICALS, LP | 2002-04-23 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| US-20010007848-A1 | Single-site catalysts for olefin polymerization | EQUISTAR CHEMICALS, L.P. | 2001-07-12 | — | — | US | disclosed |
| US-6232260-B1 | ORGANOMETALLIC COMPLEX COMPRISES A GROUP 3 TO 10 TRANSITION OR LANTHANIDE METAL, M, AND AT LEAST ONE INDENOINDOLYL LIGAND THAT IS .PI.-BONDED TO M. | EQUISTAR CHEMICALS, L.P. | 2001-05-15 | — | — | US | disclosed |
| WO-2001027125-A1 | SINGLE-SITE CATALYSTS FOR OLEFIN POLYMERIZATION | EQUISTAR CHEMICALS, L.P. (US) | 2001-04-19 | — | — | WO | disclosed |
| US-5620973-A | CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0655451-A1 | Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | ALDH1A1 1143/4885MAPT 1113/4885PKM 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.